Robert Shorr, Ph.D, D.I.C, CEO, Cornerstone Pharmaceuticals, discusses how physicians can understand a new oncology drug, starting with knowing its safety limitations. He also explains the structure and purpose of Phase 1 and 2 clinical trials.

Reading:
Richey EA, Lyons EA, Nebeker JR, Shankaran V, McKoy JM, Luu TH, Nonzee N, Trifilio S, Sartor O, Benson AB 3rd, Carson KR, Edwards BJ, Gilchrist-Scott D, Kuzel TM, Raisch DW, Tallman MS, West DP, Hirschfeld S, Grillo-Lopez AJ, Bennett CL. Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs? J Clin Oncol. 2009 Jul 27.

Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. Le Tourneau C, Lee JJ, Siu LL. J Natl Cancer Inst. 2009 May 20;101(10):708-20. Epub 2009 May 12. Review.

Sponsored by The Doctor’s Channel